FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.416,11 +675,96 (+1,15%)
Hercules Capital, Inc. (HTGC)
Dopo ore:
| Chiusura precedente | 18,95 |
| Aperto | 18,93 |
| Denaro | 19,00 x 1400 |
| Lettera | 19,25 x 1400 |
| Min-Max giorno | 18,89 - 19,26 |
| Intervallo di 52 settimane | 12,40 - 19,26 |
| Volume | |
| Media Volume | 925.117 |
| Capitalizzazione | 3,093B |
| Beta (5 anni mensile) | 1,32 |
| Rapporto PE (ttm) | 8,26 |
| EPS (ttm) | 2,31 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | 1,92 (10,07%) |
| Data ex dividendo | 27 feb 2024 |
| Stima target 1A | 18,67 |
GlobeNewswireX4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced that it drew down $22.5 million upon the transaction’s closing. “This expanded loan facility creates significant financial flexibility for X4 a
GlobeNewswireCOMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the Company has entered into a term loan agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million. Kabir Nath, COMPASS Pathways Chief Executive Officer said, “COMPASS is pleased to partner with Hercules for this source of non-dilutive financing to support our COMP360 phas
